Abstract
Protein tyrosine phosphorylation regulates virtually all aspects of cellular function. Proper levels of protein tyrosine phosphorylation are controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs). Deregulation of tyrosine phosphorylation-mediated signaling is a major cause of cancer. Indeed, PTKs represent an important class of anti-cancer drug targets with more than 20 drugs already approved by the FDA. Several PTPs are also implicated in tumor onset, progression and metastasis, and have attracted attention as potential therapeutic targets for cancer treatment. The most recognized members of the PTP family include PTP1B, SHP2, CDC25, and PRLs. PTP1B plays a positive role in breast cancer progression; SHP2 germ line and somatic gain-of-function mutations cause Noonan Syndrome, juvenile myelomonocytic leukemia, acute myeloid leukemia, and solid tumors; CDC25 regulates cell cycle progression and is overexpressed in a number of human cancers; and the PRLs are overexpressed in cancer and have been linked to tumor metastasis. Hence, inhibitors directed against these PTPs can serve as potential novel anti-cancer agents. This chapter provides an overview of the mechanisms of these oncogenic PTPs in promoting cancer, the approaches for inhibitor discovery, as well as the current status of drug development targeting these phosphatases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hunter T. Cell. 1999;80:225–36.
Cohen P, Alessi DR. ACS Chem Biol. 2013;8:96–104.
Alonso A, Sasin J, Bottini N, et al. Cell. 2004;117:699–711.
Tonks NK. Nat Rev Mol Cell Biol. 2006;7:833–46.
Tonks NK, Neel BG. Curr Opin Cell Biol. 2001;13:182–95.
Zhang ZY. Curr Opin Chem Biol. 2001;5:416–23.
Hardy S, Tremblay ML. Curr Oncol. 2008;15:5–8.
Jiang ZX, Zhang ZY. Cancer Metastasis Rev. 2008;27:263–72.
Julien SG, Dubé N, Hardy S, et al. Nat Rev Cancer. 2011;11:35–49.
McCain DF, Zhang ZY. Tyrosine phosphatases in cancer: targets for therapeutic intervention. In: Joaquin A, Denis A, editors. Topics in current genetics, vol. 5. Berlin: Springer; 2004. p. 359–74.
Ostman A, Hellberg C, Böhmer FD. Nat Rev Cancer. 2006;6:307–20.
Brown-Shimer S, Johnson KA, Lawrence JB, et al. Proc Natl Acad Sci U S A. 1990;87:5148–52.
Chernoff J, Schievella AR, Jost CA, et al. Proc Natl Acad Sci U S A. 1990;87:2735–9.
Tonks NK, Diltz CD, Fischer EH. J Biol Chem. 1988;263:6722–30.
Tonks NK, Diltz CD, Fischer EH. J Biol Chem. 1988;263:6731–7.
Frangioni JV, Beahm PH, Shifrin V, et al. Cell. 1992;68:545–60.
Woodford-Thomas TA, Rhodes JD, Dixon JE. J Cell Biol. 1992;117:401–14.
Zhang ZY, Lee SY. Expert Opin Investig Drugs. 2003;12:223–33.
Ahmad F, Li PM, Meyerovitch J, et al. J Biol Chem. 1995;270:20503–8.
Zhang S, Zhang ZY. Drug Discov Today. 2007;12:373–81.
Elchebly M, Payette P, Michaliszyn E, et al. Science. 1999;283:1544–8.
Klaman LD, Boss O, Peroni OD, et al. Mol Cell Biol. 2000;20:5479–89.
Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. Dev Cell. 2002;2:489–95.
Lessard L, Stuible M, Tremblay ML. Biochim Biophys Acta. 2009;1804:613–9.
Bjorge JD, Pang A, Fujita DJ. J Biol Chem. 2000;275:41439–46.
Dubé N, Cheng A, Tremblay ML. Proc Natl Acad Sci U S A. 2004;101:1834–9.
Julien SG, Dubé N, Read M, et al. Nat Genet. 2007;39:338–46.
Wiener JR, Kerns BJ, Harvey EL, et al. J Natl Cancer Inst. 1994;86:372–8.
Bentires-Alj M, Neel BG. Cancer Res. 2007;67:2420–4.
Combs AP. J Med Chem. 2010;53:2333–44.
You-Ten KE, Muise ES, Itié A, et al. J Exp Med. 1997;186:683–93.
Heinonen KM, Nestel FP, Newell EW, et al. Blood. 2004;103:3457–64.
Puius YA, Zhao Y, Sullivan M, et al. Proc Natl Acad Sci U S A. 1997;94:13420–5.
Shen K, Keng YF, Wu L, et al. J Biol Chem. 2001;276:47311–9.
Sun JP, Fedorov AA, Lee SY, et al. J Biol Chem. 2003;278:12406–14.
Xie L, Lee SY, Andersen JN, et al. Biochemistry. 2003;42:12792–804.
Lee SY, Liang F, Guo XL, et al. Angew Chem Int Ed Engl. 2005;44:4242–4.
Boutselis IG, Yu X, Zhang ZY, et al. J Med Chem. 2007;50:856–64.
Han Y, Belley M, Bayly CI, et al. Bioorg Med Chem Lett. 2008;18:3200–5.
Lantz KA, Hart SG, Planey SL, et al. Obesity. 2010;18:1516–23.
Mclane M, Ruiz-White, I, Wolfe, H, et al. PCT Int Appl WO 2009/032321 (2009).
Shrestha S, Bhattarai BR, Cho H, et al. Bioorg Med Chem Lett. 2007;17:2728–30.
Wiesmann C, Barr KJ, Kung J, et al. Nat Struct Mol Biol. 2004;11:730–7.
Bhanot S, Monia BP, Geary RS, et al. PCT Int Appl WO 2006/044531 (2006).
Geary RS, Bradley JD, Watanabe T, et al. Clin Pharmacokinet. 2006;45:789–801.
Rondinone CM, Trevillyan JM, Clampit J, et al. Diabetes. 2002;51:2405–11.
He R, Zeng LF, He Y, et al. Recent advances in PTP1B inhibitor development for the treatment of type-2 diabetes and obesity. In: Jones RM, editor. New therapeutic strategies for type 2 diabetes: small molecule approaches. London: RSC; 2012.
Chan RJ, Feng GS. Blood. 2007;109:862–7.
Grossmann KS, Rosário M, Birchmeier C, et al. Adv Cancer Res. 2010;106:53–89.
Mohi MG, Neel BG. Curr Opin Genet Dev. 2007;7:23–30.
Neel BG, Gu H, Pao L. Trends Biochem Sci. 2003;28:284–93.
Pao LI, Badour K, Siminovitch KA, et al. Annu Rev Immunol. 2007;25:473–523.
Freeman Jr RM, Plutzky J, Neel BG. Proc Natl Acad Sci U S A. 1992;89:11239–43.
Bentires-Alj M, Paez JG, David FS, et al. Cancer Res. 2004;64:8816–20.
Kratz CP, Niemeyer CM, Castleberry RP, et al. Blood. 2005;106:2183–5.
Loh ML, Reynolds MG, Vattikuti S, et al. Leukemia. 2004;18:1831–4.
Loh ML, Vattikuti S, Schubbert S, et al. Blood. 2004;103:2325–31.
Tartaglia M, Martinelli S, Cazzaniga G, et al. Blood. 2004;104:307–13.
Tartaglia M, Niemeyer CM, Fragale A. Nat Genet. 2003;34:148–50.
Chan G, Kalaitzidis D, Neel BG. Cancer Metastasis Rev. 2008;27:179–92.
Miyamoto D, Miyamoto M, Takahashi A, et al. Oncogene. 2008;27:3508–15.
Pugh TJ, Morozova O, Attiyeh EF, et al. Nat Genet. 2013;45:279–84.
Mattoon DR, et al. BMC Biol. 2004;2:24.
Zhang SQ, Tsiaras WG, Araki T, et al. Mol Cell Biol. 2002;22:4062–72.
Aceto N, Sausgruber N, Brinkhaus H, et al. Nat Med. 2012;18:529–37.
Chen L, Sung SS, Yip ML, et al. Mol Pharmacol. 2006;70:562–70.
Lawrence HR, Pireddu R, Chen L, et al. J Med Chem. 2008;51:4948–56.
Chen L, Pernazza D, Scott LM, et al. Biochem Pharmacol. 2010;80:801–10.
Hellmuth K, Grosskopf S, Lum CT, et al. Proc Natl Acad Sci U S A. 2008;105:7275–80.
Cheng XC, Kihara T, Ying X, et al. J Antibiot (Tokyo). 1989;42:141–4.
Shim JH, Lee HK, Chang EJ, et al. Proc Natl Acad Sci U S A. 2002;99:10617–22.
Liu S, Yu Z, Yu X, et al. Chem Biol. 2011;18:101–10.
Lee JH, Lee JS, Kim SE, et al. Mol Cancer Ther. 2006;5:3222–31.
Zhang X, He Y, Liu S, et al. J Med Chem. 2010;53:2482–93.
Sharma N, Kumar V, Everingham S, et al. Mol Cell Biol. 2012;32:2653–63.
Mali RS, Ma P, Zeng LF, et al. Blood. 2012;120:2669–78.
Nabinger SC, Li XJ, Ramdas B, et al. Leukemia. 2013;27:398–408.
Xu J, Zeng LF, Shen W, et al. Biochem Biophys Res Commun. 2013;439:586–90.
Boutros R, Dozier C, Ducommun B. Curr Opin Cell Biol. 2006;18:185–91.
Boutros R, Lobjois V, Ducommun B. Nat Rev Cancer. 2007;7:495–507.
Rudolph J. Biochemistry. 2007;46:3595–604.
Russell P, Nurse P. Cell. 1986;45:145–53.
Lyon MA, Ducruet AP, Wipf P, et al. Nat Rev Drug Discov. 2002;1:961–76.
Kristjánsdóttir K, Rudolph J. Chem Biol. 2004;11:1043–51.
Karlsson-Rosenthal C, Millar JB. Trends Cell Biol. 2006;16:285–92.
Malumbres M, Barbacid M. Trends Biochem Sci. 2005;30:630–41.
Blomberg I, Hoffmann I. Mol Cell Biol. 1999;19:6183–94.
Millar JB, Blevitt J, Gerace L. Proc Natl Acad Sci U S A. 1991;88:10500–4.
Gabrielli BG, Clarck JM, McCormack A, et al. J Biol Chem. 1997;272:28607–14.
Galaktionov K, Lee AK, Eckstein J, et al. Science. 1995;269:1575–7.
Ma ZQ, Chua SS, DeMayo FJ, et al. Oncogene. 1999;18:4564–76.
Yao Y, Slosberg ED, Wang L, et al. Oncogene. 1999;18:5159–66.
McCarthy PJ, Kelly-Borges M, Lobkovsky E, et al. J Am Chem Soc. 1996;118:8759–60.
Takahashi M, Dodo K, Sugimoto Y, et al. Bioorg Med Chem Lett. 2000;10:2571–4.
Brohm D, Metzger S, Bhargava A, et al. Angew Chem Int Ed Engl. 2002;41:307–11.
Tsuchiya A, Hirai G, Koyama Y, et al. ACS Med Chem Lett. 2012;3:294–8.
Lazo JS, Nemoto K, Pestell KE, et al. Mol Pharmacol. 2002;61:720–8.
Lazo JS, Aslan DC, Southwick EC, et al. J Med Chem. 2001;44:4042–9.
Brezak MC, Quaranta M, Contour-Galcera MO, et al. Mol Cancer Ther. 2005;4:1378–87.
Cazales M, Boutros R, Brezak MC, et al. Mol Cancer Ther. 2007;6:318–25.
Galcera-Contour MO, Bigg D, Prevost G, et al. PCT Int Appl WO 2006/067311 (2006).
Siddik ZH, editor. Checkpoint controls and targets in cancer therapy. Totowa: Humana Press; 2009. p. 265.
Lavecchia A, Di Giovanni C, Novellino E. Mini Rev Med Chem. 2012;12:62–73.
Wang X, Thomas B, Sachdeva R, et al. Proc Natl Acad Sci U S A. 2006;103:3604–9.
Bessette DC, Qiu D, Pallen CJ. Cancer Metastasis Rev. 2008;27:231–52.
Rios P, Li X, Köhn M. FEBS J. 2013;280:505–24.
Diamond RH, Cressman DE, Laz TM, et al. Mol Cell Biol. 1994;14:3752–62.
Mohn KL, Laz TM, Hsu JC, et al. Mol Cell Biol. 1991;11:381–90.
Sun JP, Wang WQ, Yang H, et al. Biochemistry. 2005;44:12009–21.
Zeng Q, Si X, Horstmann H, et al. J Biol Chem. 2000;275:21444–52.
Achiwa H, Lazo JS. Cancer Res. 2007;67:643–50.
Liang F, Liang J, Wang WQ, et al. J Biol Chem. 2007;282:5413–9.
Min SH, Kim DM, Heo YS, et al. Oncogene. 2009;28:545–54.
Jiang Y, Liu XQ, Rajput A, et al. Cancer Res. 2011;71:234–44.
Min SH, Kim DM, Heo YS, et al. Life Sci. 2010;86:66–72.
Luo Y, Liang F, Zhang ZY. Biochemistry. 2009;48:1838–46.
Peng L, Xing X, Li W, et al. Mol Cancer. 2009;8:110.
Bai Y, Luo Y, Liu S, et al. J Biol Chem. 2011;286:42316–24.
Fiordalisi JJ, Keller PJ, Cox AD. Cancer Res. 2006;66:3153–61.
Wang H, Quah SY, Dong JM, et al. Cancer Res. 2007;67:2922–6.
Wang Y, Li ZF, He J, et al. Int J Colorectal Dis. 2007;22:1179–84.
Nakashima M, Lazo JS. J Pharmacol Exp Ther. 2010;334:627–33.
Stephens B, Han H, Hostetter G. Mol Cancer Ther. 2008;7:202–10.
Hardy S, Wong NN, Muller WJ, et al. Cancer Res. 2010;70:8959–67.
Wang Y, Lazo JS. Oncogene. 2012;31:818–27.
Yagi T, Morimoto A, Eguchi M, et al. Blood. 2003;102:1849–56.
Peng L, Ning J, Meng L, et al. J Cancer Res Clin Oncol. 2004;130:521–6.
Zeng Q, Dong JM, Guo K, et al. Cancer Res. 2003;63:2716–22.
Kato H, Semba S, Miskad UA, et al. Clin Cancer Res. 2004;10:7318–28.
Rouleau C, Roy A, St Martin T, et al. Mol Cancer Ther. 2006;5:219–29.
Pathak MK, Dhawan D, Lindner DJ, et al. Mol Cancer Ther. 2002;1:1255–64.
Farinotti R, Pascaud MB, Girard PM, et al. J Infect Dis. 1989;160:507–12.
Stephens BJ, Han H, Gokhale V, et al. Mol Cancer Ther. 2005;4:1653–61.
Ahn JH, Kim SJ, Park WS, et al. Bioorg Med Chem Lett. 2006;16:2996–9.
Choi SK, Oh HM, Lee SK, et al. Nat Prod Res. 2006;20:341–6.
Daouti S, Li WH, Qian H, et al. Cancer Res. 2008;68:1162–9.
Defilippi P, Di Stefano P, Cabodi S. Trends Cell Biol. 2006;16:257–63.
Jeong DG, Kim SJ, Kim JH, et al. J Mol Biol. 2005;345:401–13.
Sun JP, Luo Y, Yu X, et al. J Biol Chem. 2007;282:29043–51.
Bialy L, Waldmann H. Angew Chem Int Ed Engl. 2005;44:3814–39.
Hooft van Huijsduijnen R, Bombrun A, Swinnen D. Drug Discov Today. 2002;7:1013–9.
Vintonyak VV, Antonchick AP, Rauh D, et al. Curr Opin Chem Biol. 2009;13:272–83.
Acknowledgments
This work was supported in part by National Institutes of Health Grant CA152194.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
He, R., Zhang, ZY. (2016). Current Status of PTP-Based Therapeutics. In: Neel, B., Tonks, N. (eds) Protein Tyrosine Phosphatases in Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3649-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3649-6_13
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3647-2
Online ISBN: 978-1-4939-3649-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)